Supriya Lifescience Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Press Release- Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025.".
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience Limited has shared a press release with the exchange covering its unaudited financial results for the third quarter (October–December 2025) and the nine-month period ending December 31, 2025. The detailed figures are contained in the attached press release rather than disclosed in this filing. Supriya Lifescience is an active pharmaceutical ingredients (API) manufacturer, and this is a routine quarterly results disclosure ahead of the company's formal Q3 earnings submission. Investors would need to refer to the attached press release to see specific revenue, EBITDA, and profit numbers.
This is a standard quarterly results announcement and is unlikely to cause any immediate stock price movement on its own. The actual market reaction will depend on the revenue growth, margin trends, and guidance numbers within the detailed results, which investors should review once the full press release is published.